Literature DB >> 23428846

Slow-release oral morphine sulfate abuse: results of the postmarketing surveillance systems for psychoactive prescription drug abuse in France.

Hélène Peyriere1, Céline Eiden, Joëlle Micallef, Maryse Lapeyre-Mestre, Jean-Luc Faillie, Jean-Pierre Blayac.   

Abstract

BACKGROUND: Few data are available concerning the diversion and abuse of morphine sulfate. In France, morphine sulfate abuse is currently investigated by the health authorities. The aim of our study was to provide data on morphine sulfate abuse in France, collected during the period 1996-2011.
METHODS: The French monitoring system for psychoactive medication abuse collected data from several sources: spontaneous reporting of cases of abuse or dependence (NotS; 'Notifications Spontanées'), specific periodic surveys from specialized care centers (OPPIDUM; 'Observation des Produits Psychotropes Illicites ou Détournés de leur Utilisation Médicamenteuse'), and community pharmacists (OSIAP; 'Ordonnances Suspectes Indicateur d'Abus Possible').
RESULTS: A total of 649 cases (75% men, median age: 34 years) were spontaneously reported: 578 cases of abuse and 71 cases of use as opiate maintenance treatment. The medication formulation was Skenan(®) (614 cases), and Moscontin(®) (35 cases). All surveys (NotS, OPPIDUM, and OSIAP) showed an overrepresentation of Skenan(®) (87.9-94.6% of cases) that was intravenously injected in 60.4-61.2% of the cases. Data analysis showed that patients abusing morphine sulfate have a long history of drug abuse and a history of polydrug use.
CONCLUSION: All the data presented in this study highlight the level of morphine sulfate abuse, specify the modalities of use (intravenous route), and show the risks associated with abuse (infectious diseases). This study outlines the usefulness of our epidemiological tools, and provides evidence supporting intensive surveillance.
Copyright © 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23428846     DOI: 10.1159/000346179

Source DB:  PubMed          Journal:  Eur Addict Res        ISSN: 1022-6877            Impact factor:   3.015


  5 in total

1.  Detection of signals of abuse and dependence applying disproportionality analysis.

Authors:  V Pauly; M Lapeyre-Mestre; D Braunstein; M Rueter; X Thirion; E Jouanjus; J Micallef
Journal:  Eur J Clin Pharmacol       Date:  2014-11-20       Impact factor: 2.953

2.  Oral Morphine as an Alternative Substitution Treatment for Opioid Use Disorder, a Rare but Non-risk-free Use.

Authors:  Célian Bertin; Julien Bezin; Chouki Chenaf; Jessica Delorme; Nicolas Kerckhove; Antoine Pariente; Marie Tournier; Nicolas Authier
Journal:  Front Psychiatry       Date:  2022-06-30       Impact factor: 5.435

3.  Risk assessment of using off-label morphine sulfate in a population-based retrospective cohort of opioid-dependent patients.

Authors:  Célian Bertin; Jessica Delorme; Marie Riquelme; Hélène Peyrière; Georges Brousse; Alain Eschalier; Denis Ardid; Chouki Chenaf; Nicolas Authier
Journal:  Br J Clin Pharmacol       Date:  2019-08-24       Impact factor: 4.335

4.  Willingness to receive intravenous buprenorphine treatment in opioid-dependent people refractory to oral opioid maintenance treatment: results from a community-based survey in France.

Authors:  Perrine Roux; Daniela Rojas Castro; Khadim Ndiaye; Laélia Briand Madrid; Virginie Laporte; Marion Mora; Gwenaelle Maradan; Stéphane Morel; Bruno Spire; Patrizia Carrieri
Journal:  Subst Abuse Treat Prev Policy       Date:  2017-11-02

5.  Aspiration in lethal drug abuse-a consequence of opioid intoxication.

Authors:  Johannes Nicolakis; Günter Gmeiner; Christian Reiter; Monika Heidemarie Seltenhammer
Journal:  Int J Legal Med       Date:  2020-09-14       Impact factor: 2.686

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.